Related Experiment Video
Updated: Aug 17, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
Gankyrin: an intriguing name for a novel regulator of p53 and RB
Guillermina Lozano1, Gerard P Zambetti
1The University of Texas M.D. Anderson Cancer Center, Department of Molecular Genetics, Section of Cancer Genetics, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Abstract:
The RB and p53 tumor suppressors lie at the heart of cancer biology, and inactivation of both pathways is seemingly essential for tumor development. Previous studies identified gankyrin as a component of the 26S proteasome that is consistently overexpressed in liver cancer and promotes cell transformation by binding RB. In the current issue of Cancer Cell, Fujita and colleagues (Higashitsuji et al., 2005) show that gankyrin also binds MDM2 and facilitates its destruction of p53. These important findings implicate gankyrin as a dual-purpose negative regulator of RB and p53, thereby identifying gankyrin as a rational cancer therapeutic target.
Insights
Gankyrin, a protein overexpressed in liver cancer, promotes tumor development by targeting both RB and p53 tumor suppressors. This dual action makes gankyrin a promising therapeutic target for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- RB and p53 are critical tumor suppressors, and their inactivation is crucial for cancer development.
- Gankyrin is a 26S proteasome component overexpressed in liver cancer, known to bind RB and promote cell transformation.
Purpose of the Study:
- To investigate the role of gankyrin in the p53 pathway.
- To elucidate the dual function of gankyrin as a negative regulator of both RB and p53.
Main Methods:
- Co-immunoprecipitation assays to detect protein-protein interactions.
- Western blotting to analyze protein levels and degradation.
- Cellular transformation assays.
Main Results:
- Gankyrin binds to MDM2, a key regulator of p53.
- Gankyrin facilitates MDM2-mediated degradation of p53.
- Gankyrin acts as a dual inhibitor of both RB and p53 pathways.
Conclusions:
- Gankyrin is implicated as a dual-purpose negative regulator of RB and p53 tumor suppressors.
- These findings identify gankyrin as a potential therapeutic target for liver cancer and other malignancies involving RB/p53 pathway alterations.
Related Concept Videos
Negative Regulator Molecules
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
The Ras Gene
Ras is a superfamily...
Positive Regulator Molecules
